2016 UCD VentureLaunch Accelerator Programme Participants

The 5 new ventures participating on the 2016 UCD VentureLaunch Accelerator Programme are profiled below.

Click here to find out more about the 2016 VentureLaunch Accelerator Programme Showcase and Awards event on 16 November (5:15 pm - 7 pm)  and to register to attend the event.

VentureLaunch 2016 participants
Pictured outside NovaUCD are participants on the 2016 UCD VentureLaunch Accelerator Programme

BioPure has developed a proprietary technology that produces an exceptionally pure (>98%) natural antioxidant known as Hydroxytyrosol (HT). Antioxidants are extremely powerful ingredients for the cosmetic, food and health industries. BioPure can produce HT 3 times cheaper and a production rate of 30 times faster than any market competitor. The founders of BioPure are Professor Kevin O’Connor, Dr Reeta Davis and Caroline Byrne, UCD School of Biomolecular and Biomedical Science and UCD Earth Institute.

Cortex Analyticsprovides the Total Patient Value (TPV) toolkit, a new data-analytics measurement system for pharma/medtech companies. The toolkit will enable them to identify key patient outcomes earlier in drug/product development. It identifies key metrics relating to patient adherence and willingness to pay, to enhance decision-making to reduce development costs, as well as facilitatingproduct marketing to improve sales. The founder of Cortex Analytics is Dr Daniel Regan,UCD School of Psychology. 

Dubrand protects medical device brands. DuBrand’s novel technology for applying a bar code provides anti-counterfeit protection and traceability for medical device parts, meeting stringent industry regulations. The founders of Dubrand are Dr Eamonn Ahearne, Dr Diego Carou and Dr Jinghang Liu, UCD School of Mechanical and Materials Engineering.

EpiCor Therapeutics is developing new disease-modifying treatments that target the mechanisms underlying the development of heart failure. The current focus of EpiCor Therapeutics is to repurpose an existing drug, 5-azacytidine, for the treatment of a devastating orphan designated heart disease called hypertrophic obstructive cardiomyopathy. The founders of EpiCor Therapeutics areDr John Baugh, Dr Nadia Glezeva, Dr Chris Watson, Dr Mark Ledwidge and Professor Ken McDonald, UCD School of Medicine.

Latch Medical is developing a revolutionary tissue anchorage system based on microtechnology. Where surgery is necessary, the cutting of skin is mandated, but existing methods of invasive wound closure are meticulous, time-consuming and promote infection risk and scarring. By eliminating the need to penetrate the full-thickness of the skin, Latch Medical’s Relialoc Skin Closure System can decrease infection risk, improve cosmetic outcomes and save operative time. The founders of Latch Medical are Dr Seamus Morris and Dr Nicky Bertollo, UCD School of Medicine and Dr Eoin O’Cearbhaill, UCD School of Mechanical and Materials Engineering.

Click here to find out more about the 2016 VentureLaunch Accelerator Programme Showcase and Awards event on 16 November (5:15 pm - 7 pm)  and to register to attend the event.

Event hashtag: #VentureLaunch16

SHARE